Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines.
We have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.
G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.
Current Team (5)Update
Funding Rounds (4) - $129MUpdate
Board Members and Advisors (2)Update
Forest Laboratories, Inc. (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track...
Venture capital Firm
Polaris Partners is a venture company investing in digital media, life sciences, and enterprise...
Alta Partners is a leading venture capital firm in life sciences, funding over 130 companies in...
Global venture capital firm helping entrepreneurs build transformational businesses across...
1018 West 8th Avenue
King Of Prussia, PA 19406